AnaptysBio (NASDAQ:ANAB) had its price target lifted by Stifel Nicolaus from $130.00 to $139.00 in a research report released on Tuesday, MarketBeat reports. The firm currently has a buy rating on the biotechnology company’s stock.
Other research analysts also recently issued research reports about the stock. Wedbush restated an outperform rating and set a $142.00 price objective on shares of AnaptysBio in a research report on Tuesday, February 20th. Jefferies Group assumed coverage on shares of AnaptysBio in a research report on Thursday, November 9th. They set a buy rating and a $101.00 price objective on the stock. SunTrust Banks increased their price objective on shares of AnaptysBio from $115.00 to $162.00 and gave the company a buy rating in a research report on Thursday, February 15th. ValuEngine upgraded shares of AnaptysBio from a sell rating to a hold rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research downgraded shares of AnaptysBio from a buy rating to a hold rating in a research report on Tuesday, January 2nd. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $129.67.
AnaptysBio (NASDAQ ANAB) opened at $116.87 on Tuesday. AnaptysBio has a 52-week low of $18.15 and a 52-week high of $134.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 17.93 and a quick ratio of 10.77.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. New York State Common Retirement Fund raised its position in AnaptysBio by 21.4% in the third quarter. New York State Common Retirement Fund now owns 8,500 shares of the biotechnology company’s stock worth $297,000 after acquiring an additional 1,500 shares during the period. Teachers Advisors LLC raised its position in shares of AnaptysBio by 23.4% during the 2nd quarter. Teachers Advisors LLC now owns 9,520 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 1,807 shares during the period. Alps Advisors Inc. raised its position in shares of AnaptysBio by 10.0% during the 3rd quarter. Alps Advisors Inc. now owns 20,034 shares of the biotechnology company’s stock valued at $700,000 after purchasing an additional 1,824 shares during the period. Legal & General Group Plc raised its position in shares of AnaptysBio by 160.8% during the 3rd quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 1,951 shares during the period. Finally, Two Sigma Securities LLC bought a new stake in shares of AnaptysBio during the 4th quarter valued at $212,000.
AnaptysBio Company Profile
AnaptysBio, Inc is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.